Neurodegenerative Diseases Drugs Market Size, Share and Industry Analysis By Drug Class (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), By Disease Indication (Multiple Sclerosis, Parkinson’s Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA), Others), By Route of Administration (Oral, Injection, Transdermal, Others), By End User and Regional Forecast 2026-2034

The global neurodegenerative diseases drugs market size was valued at USD 58.22 billion in 2025. The market is projected to grow from USD 62.79 billion in 2026 to USD 93.09 billion by the end of 2034, exhibiting a CAGR of 5.05% during the forecast period 2025-2032. North America dominated the neurodegenerative diseases drugs market with a market share of 48.53% in 2025.

The neurodegenerative disease continues to pose a substantial burden on global healthcare cost as well as on mental and physical health of the populations. Neurodegenerative diseases include all the diseases that affect the neurons of the human brain. Alzheimer’s disease is the most prevalent neurodegenerative disease, with 5.8 million estimated cases of Alzheimer's dementia in 2019 in the U.S alone. Other neurodegenerative diseases include Parkinson’s Disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, spinal muscular atrophy, multiple system atrophy, and others.

The increasing prevalence of neurodegenerative diseases is the primary reason for the increased demand for neurodegenerative diseases drugs. The higher potential and future business opportunities in the neurodegenerative diseases drugs market have accelerated clinical research and encouraged huge R&D investments, strategic collaborations, and new product launch. For example, Adamas Pharmaceuticals, Inc. is conducting phase 3 clinical study on ADS-5102, an investigational amantadine agent for the treatment of patients with multiple sclerosis.

Download Free sample to learn more about this report.

Neurodegenerative Diseases Drugs Market Snapshot & Highlights

Market Size & Forecast:

• 2025 Market Size: USD 58.22 billion
• 2026 Market Size: USD 62.79 billion
• 2034 Forecast Market Size: USD 93.09 billion
• CAGR: 5.05% from 2026 to 2034

Market Share:

• North America dominated the neurodegenerative diseases drugs market with a 48.53% share in 2025, driven by high drug demand, premium pricing, substantial R&D investments, and favorable reimbursement policies.
• By disease indication, the multiple sclerosis segment holds the largest market share due to high drug pricing, positive government recommendations, and new product launches such as the FDA-approved drug Mayzent.

Key Country Highlights:

• Japan: Growing demand supported by co-promotion agreements (e.g., Biogen and Eisai for Tecfidera, Tysabri, Avonex) and increasing prevalence of neurodegenerative diseases.
• United States: Market growth fueled by FDA approvals (e.g., Mayzent for multiple sclerosis, Inbrija for Parkinson’s disease), strategic R&D investments, and active pipeline development.
• China: Increasing geriatric population and rising prevalence of Alzheimer's and Parkinson's diseases are driving demand, alongside expanding healthcare infrastructure.
• Europe: Considerable growth due to government support and approvals such as SPINRAZA for spinal muscular atrophy, alongside rising patient population and healthcare funding.

Market Segmentation

By Disease Indication

FDA Approval of Mayzent to Surge the Multiple Sclerosis Segment 

The multiple sclerosis segment accounted for the largest market share of 62.57% in 2026 and is estimated to retain its dominance throughout the forecast period. The segment’s leadership is supported by the comparatively high pricing of disease-modifying therapies and consistent uptake of long-term treatment regimens across developed markets.

Additionally, supportive government recommendations and the introduction of novel therapies have reinforced segment performance. The FDA approval of Mayzent in March 2019 further strengthened the multiple sclerosis treatment landscape, contributing to sustained revenue generation within the global neurodegenerative diseases drugs market.

Spinal muscular atrophy shows accelerated growth driven by limited therapeutic competition

The spinal muscular atrophy segment is projected to register rapid growth during the forecast period. This growth is primarily attributed to the successful commercial adoption of SPINRAZA and the limited availability of alternative approved therapies within this indication.

The concentrated competitive environment and high treatment costs associated with spinal muscular atrophy therapies continue to support strong revenue expansion, positioning the segment as a key growth contributor over the study period.

To know how our report can help streamline your business, Speak to Analyst

By Drug Class

Immunomodulators and interferons benefit from established clinical use

Based on drug class, the market is segmented into immunomodulators, interferons, decarboxylase inhibitors, dopamine agonists, and others. Immunomodulators and interferons account for a substantial share due to their long-standing use in managing chronic neurodegenerative conditions, particularly multiple sclerosis, with a market share of 44.98% in 2026.

The widespread clinical acceptance of these drug classes, supported by robust prescribing practices and reimbursement frameworks, underpins their continued utilization across major healthcare systems.

By Route of Administration

Oral administration leads due to treatment convenience and policy endorsement

The oral segment accounted for the maximum market with a share of 49.34% in 2026. Its dominance is supported by active government recommendations and a strong preference for orally administered therapies within long-term disease management protocols.

Oral formulations enable easier integration into routine treatment regimens, contributing to higher adoption across hospital and outpatient care settings.

By Distribution Channel

Hospital pharmacies remain central to therapy access

Based on distribution channel, the market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. Hospital pharmacies hold a key position due to their role in dispensing high-cost and specialty neurodegenerative drugs, particularly during diagnosis and treatment initiation phases. The hospital pharmacy segment is projected to dominate the market with a share of 48.49% in 2026.

Retail and online pharmacies support ongoing therapy access, especially for maintenance medications, contributing to broader market coverage and continuity of care.    

Regional Analysis

North America

To get more information on the regional analysis of this market, Download Free sample

"North America to Dominate the Neurodegenerative Diseases Drugs Market "

North America generated USD 28.25 billion in revenue in 2025 and is expected to dominate the neurodegenerative diseases drugs market throughout the forecast period. Market leadership is supported by strong demand for branded therapies, high drug pricing, and increased R&D investments, along with favorable reimbursement policies that enable early adoption of innovative treatments. High diagnosis rates and large treated patient populations across the United States and Canada further reinforce regional dominance. The U.S. market is projected to reach USD 25.83 billion by 2026.

Europe

The neurodegenerative diseases drugs market in Europe is projected to witness considerable growth, driven by active government support and regulatory approvals for innovative therapies, including the marketing approval for SPINRAZA in June 2017. Well-established public healthcare systems and expanding access to disease-modifying treatments across Germany, France, the United Kingdom, Italy, and Spain continue to support sustained market expansion. The UK market is projected to reach USD 2.82 billion by 2026, while the Germany market is projected to reach USD 3.3 billion by 2026.

Asia Pacific

Asia Pacific is estimated to register the highest CAGR during the forecast period, owing to the rising prevalence of neurodegenerative diseases, rapidly growing geriatric population, and increasing demand for Alzheimer’s and Parkinson’s disease drugs, particularly in Japan and China. Improving healthcare infrastructure, expanding pharmaceutical distribution networks, and rising healthcare expenditure in countries such as India, South Korea, and Australia are further accelerating regional growth. The Japan market is projected to reach USD 3.07 billion by 2026, while the China market is projected to reach USD 2.94 billion by 2026, and the India market is projected to reach USD 2.64 billion by 2026.

Latin America

Latin America is expected to grow steadily due to improving awareness of neurodegenerative disorders and gradual expansion of access to neurological treatments. Countries such as Brazil and Mexico are witnessing higher diagnosis rates and increased availability of branded and generic therapies through public and private healthcare systems.

Middle East & Africa

The Middle East & Africa market growth is anticipated with increasing healthcare investments, rising awareness of age-related neurological disorders, and improvements in diagnostic capabilities. Expanding access to specialty care in countries including Saudi Arabia, the UAE, and South Africa is expected to support gradual uptake of neurodegenerative disease drugs over the forecast period.

Key Market Drivers

"Biogen, F. Hoffmann-La Roche Ltd, to Account for More Than Half of the Market Share in Terms of Revenue "

Biogen has emerged as a leading player in the global market owing to the higher sales of Tecfidera in 2024, the launch of SPINRAZA, and strategic partnership for increased distribution of drugs. F. Hoffmann-La Roche Ltd. is ranked second in the global market owing to the launch of Ocrevus and higher sales of Madopar. However, Novartis AG is predicted to gain a maximum of the global neurodegenerative diseases drugs market shares during the forecast period due to the higher demand for Gilenya.

Novartis AG is also expected to benefit by the National Institute for Health and Care Excellence (NICE) decision in 2018 to recommend Extavia for the treatment of relapsing-remitting multiple sclerosis or secondary progressive multiple sclerosis. Other players operating in the global neurodegenerative diseases drugs market are Pfizer, Inc., Merck & Co., Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Orion Pharma, UCB S.A, ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation and other players.

List of Companies Profiled

• Biogen
• Pfizer, Inc.
• Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Novartis AG
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Orion Pharma
• UCB S.A
• ACADIA Pharmaceuticals Inc.
• Lundbeck A/S
• Mitsubishi Tanabe Pharma Corporation
• Other players 

Report Coverage

Neurodegenerative diseases refer to the neurological diseases that mainly affect the neurons of human brains. Neurodegenerative disease imposes not only a substantial burden on global healthcare cost but also on the mental and physical health of the population. Alzheimer’s Disease, Parkinson’s Disease, Multiple sclerosis, and amyotrophic lateral sclerosis are the major neurodegenerative diseases. According to the European Multiple Sclerosis Platform (EMSP), approximately 762,760 people in Europe were estimated to have multiple sclerosis in 2015.

According to the European Parkinson’s Disease Association, more than 1.2 million people in Europe are living with Parkinson’s Disease, which is expected to double by 2030. Neurodegenerative diseases advance with age; the number of neurodegenerative diseases cases is expected to increase dramatically as the life span of people in many countries continues to increase. Molecular epidemiology and molecular techniques such as genomics, proteomics, and others have provided better insights into the diseases resulting in increased research on novel therapy and presence of potential pipeline drugs candidates. Government research grants, strategic research collaborations, high pricing of the drugs, and active government support have resulted in a huge surge in demand for neurodegenerative diseases drugs.

The report provides qualitative and quantitative insights on the neurodegenerative diseases drugs industry and detailed analysis of neurodegenerative diseases drugs market size and growth rate for all possible segments in the market. The market is segmented by drug class, by disease indication, by route of administration, by distribution channel, and by region. On the basis of the drug class, the global market is segmented into immunomodulator, interferons, decarboxylase inhibitors, dopamine agonists, and others.

Based on disease indication, the global neurodegenerative diseases drugs market is categorized into multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, spinal muscular atrophy, and others. In terms of the route of administration, the market is divided into oral, injection and transdermal. Various distribution channels covered under the report are hospital pharmacy, retail pharmacy, and online pharmacy. Geographically, the market is segmented into four major regions, which are North America, Europe, Asia Pacific, Latin America, the Middle East & Africa. The regions are further categorized into countries.

Along with this, the report provides an elaborative analysis of the market dynamics and competitive landscape. The report offers key insights on the prevalence of neurodegenerative diseases for key countries, pipeline analysis, patent snapshot, regulatory scenario for key countries, new product launch, recent industry developments such as mergers & acquisitions, the regulatory scenario in key countries, and key industry trends. 

To gain extensive insights into the market, Download for Customization

Key Industry Developments

• In March 2019, Novartis AG announced the FDA approval for Mayzent, an immunomodulator for the treatment of relapsing forms of multiple sclerosis (RMS).
• In January 2018, Eisai Co., Ltd. collaborated with Biogen for the co-promotion of TECFIDERA, TYSABRI, and AVONEX in Japan.
• In February 2017, Apitope, a company for drug discovery and development announced positive results from the Phase IIa clinical study of the company’s multiple sclerosis drug candidate named ATX-MS-1467.
• In February 2019, Acorda Therapeutics launched INBRIJA, an inhalation powder to treat patient with Parkinson’s disease in the U.S.
• In June 2017, European Commission (EC) granted marketing approval for SPINRAZA, a drug used for treating spinal muscular atrophy.

Report Scope & Segmentation